Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Asia-Pacific Journal of Public Health|October 5, 2013
Cotinine levels among betel quid users and cigarette smokers in CambodiaPramil N Singh, Zuhair Natto, Rituraj Saxena, et al.
Blood Advances|August 19, 2020
A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapyDavid G Maloney, Michinori Ogura, Noriko Fukuhara, et al.
Plos One|January 26, 2012
Expression of the stress response oncoprotein LEDGF/p75 in human cancer: a study of 21 tumor typesAnamika Basu, Heather Rojas, Hiya Banerjee, et al.
Cardiovascular Diabetology|June 6, 2025
Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetesSean Wharton, Julio Rosenstock, Manige Konige, et al.
The Prostate|October 30, 2010
Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4Anamika Basu, Hiya Banerjee, Heather Rojas, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2021
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancersDirk Schadendorf, Caroline Robert, Reinhard Dummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2018
Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell CarcinomaCora N Sternberg, Frede Donskov, Naomi B Haas, et al.
Blood Cancer Journal|December 6, 2019
Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG studyMarinus van Oers, Lukas Smolej, Mario Petrini, et al.
Diabetes, Obesity & Metabolism|August 14, 2025
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetesJulio Rosenstock, Deborah A Robins, Kevin L Duffin, et al.
The Journal of ECT|May 21, 2014
Depression severity in electroconvulsive therapy (ECT) versus pharmacotherapy trialsCharles H Kellner, David C Kaicher, Hiya Banerjee, et al.
Pageof 2